R 673
Latest Information Update: 25 Jul 2006
At a glance
- Originator Roche
- Class
- Mechanism of Action Neurokinin 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders; Major depressive disorder
Most Recent Events
- 25 Jul 2006 No development reported - Phase-II for Anxiety disorders in Europe (unspecified route)
- 25 Jul 2006 No development reported - Phase-II for Anxiety disorders in USA (unspecified route)
- 25 Jul 2006 No development reported - Phase-II for Depression in Europe (unspecified route)